Ions et métaux à l’état de traces
Test | Limite inférieure | Limite supérieure | Unité | |
---|---|---|---|---|
Sodium (Na) | 135, [9] 137 [4][10] | 145, [4] [10] 147 [9] | mmol / L ou mEq / L [9] | |
310, [11] 320 [11] | 330, [11] 340 [11] | mg / dl | ||
Potassium (K) | 3,5, [4] [9] 3,6 [10] | 5,0, [4] [9] [10] 5.1 | mmol / L ou mEq / L [9] | |
14 [12] | 20 [12] | mg / dl | ||
Chlorure (Cl) | 95, [9] 98, [13]100 [4] | 105, [9] 106, [13]110 [4] | mmol / L ou mEq / L [9] | |
340 [14] | 370 [14] | mg / dl | ||
Calcium ionisé (Ca) | 1,03, [15] 1,10 [4] | 1,23, [15] 1,30 [4] | mmol / L | |
4,1, [16] 4,4 [16] | 4,9, [16] 5,2 [16] | mg / dL | ||
Calcium total (Ca) | 2,1, [9] [17] 2,2 [4] | 2,5, [4] [17] 2,6, [17] 2,8 [9] | mmol / L | |
8,4, [9] 8,5 [18] | 10,2, [9] 10,5 [18] | mg / dL | ||
Fer sérique total (TSI) – mâle | 65, [19] 76 [10] | 176, [19] 198 [10] | μg / dL | |
11,6, [20] [21]13,6 [21] | 30, [20] 32, [21]35 [21] | μmol / L | ||
Fer sérique total (TSI) – femelle | 26, [10] 50 [19] | 170 [10] [19] | μg / dL | |
4,6, [21] 8,9 [20] | 30,4 [20] | μmol / L | ||
Fer sérique total (TSI) – nouveau – nés | 100 [19] | 250 [19] | μg / dL | |
18 [21] | 45 [21] | μmol / L | ||
Fer sérique total (TSI) – enfants | 50 [19] | 120 [19] | μg / dL | |
9 [21] | 21 [21] | μmol / L | ||
Capacité totale de fixation du fer (TIBC) | 240, [19] 262 [10] | 450, [19] 474 [10] | μg / dL | |
43, [21] 47 [21] | 81, [21] 85 [21] | μmol / L | ||
Transferrin | 190, [22] 194, [4]204 [10] | 326, [4] 330, [22]360 [10] | mg / dL | |
25 [23] | 45 [23] | μmol / L | ||
La saturation de la transferrine | 20 [19] | 50 [19] | % | |
Ferritine – Mâles et femelles ménopausées | 12 [24] | 300 [24] [25] | ng / mL ou μg / L | |
27 [26] | 670 [26] | pmol / L | ||
Ferritine – femelles préménopausées | 12 [24] | 150 [24] – 200 [25] | ng / mL ou μg / L | |
27 [26] | 330 [26] – 440 [26] | pmol / L | ||
Ammoniac | 10, [27] 20 [28] | 35, [27] 65 [28] | μmol / L | |
17, [29] 34 [29] | 60, [29] 110 [29] | μg / dL | ||
Cuivre (Cu) | 70 [18] | 150 [18] | μg / dL | |
11 [30] [31] | 24 [30] | μmol / L | ||
Ceruloplasmine | 15 [18] | 60 [18] | mg / dL | |
1 [32] | 4 [32] | μmol / L | ||
Phosphate (HPO 4 2- ) | 0,8 | 1,5 [33] | mmol / L | |
Phosphore inorganique (sérum) | 1,0 [9] | 1,5 [9] | mmol / L | |
3,0 [9] | 4,5 [9] | mg / dL | ||
Zinc (Zn) | 60, [34] 72 [35] | 110, [35] 130 [34] | μg / dL | |
9.2, [36] 11 [4] | 17, [4] 20 [36] | μmol / L | ||
Magnésium | 1,5, [18] 1,7 [37] | 2,0, [18] 2,3 [37] | mEq / L ou mg / dL | |
0,6, [38] 0,7 [4] | 0,82, [38] 0,95 [4] | mmol / L |
Acides-bases et gaz du sang
Test | Artériel / veineux | Limite inférieure | Limite supérieure | Unité |
---|---|---|---|---|
pH | Artériel | 7,34, [10] 7,35 [9] | 7,44, [10] 7,45 [9] | |
Veineux | 7,31 [40] | 7.41 [40] | ||
[H + ] | Artériel | 36 [9] | 44 [9] | nmol / L |
3,6 [41] | 4,4 [41] | ng / dL | ||
Excès de base | Artériel et veineux [40] | -3 [40] | +3 [40] | mEq / L |
pression partielle d’oxygène (pO 2 ) | PO artériel 2 | 10, [9] 11 [42] | 13, [42] 14 [9] | kPa |
75, [9] [10] 83 [18] | 100, [10] 105 [9] | mmHg ou torr | ||
Veineux | 4,0 [42] | 5.3 [42] | kPa | |
30 [40] | 40 [40] | mmHg ou torr | ||
Saturation d’oxygène | Artériel | 94, [40] 95, [13] 96 [18] | 100 [13] [18] | % |
Veineux | Environ 75 [13] | |||
Pression partielle de dioxyde de carbone (PCO 2 ) | Artériel P a CO 2 | 4,4, [9] 4,7 [42] | 5,9, [9] 6,0 [42] | kPa |
33, [9] 35 [10] | 44, [9] 45 [10] | mmHg ou torr | ||
Veineux | 5,5, [42] | 6,8 [42] | kPa | |
41 [40] | 51 [40] | mmHg ou torr | ||
Teneur absolue en dioxyde de carbone (CO 2 ) | Artériel | 23 [40] | 30 [40] | mmol / L |
100 [43] | 132 [43] | mg / dL | ||
Bicarbonate (HCO 3 – ) | Artériel et veineux | 18 [18] | 23 [18] | mmol / L |
110 [44] | 140 [44] | mg / dL | ||
Bicarbonate standard (SBC e ) | Artériel et veineux | 21, 22 [9] | 27, 28 [9] | mmol / L ou mEq / L [9] |
134 [44] | 170 [44] | mg / dL |
Fonction hépatique
Test | Type de patient | Limite inférieure | Limite supérieure | Unité | commentaires |
---|---|---|---|---|---|
Protéines totales | 60, [9] 63 [10] | 78, [9] 82, [10] 84 [18] | g / L | ||
Albumine | 35 [9] [45] | 48, [10] 55 [9] | g / L | voir hypoalbuminémie | |
3,5 [10] | 4,8, [10] 5,5 [9] | U / L | |||
540 [46] | 740 [46] | μmol / L | |||
Globulins | 23 [9] | 35 [9] | g / L | ||
Bilirubine totale | 1,7, [47] 2, [9] 3,4, [47]5 [4] | 17, [9] [47] 22, [47] 25 [4] | μmol / L | ||
0,1, [9] 0,2, [10] 0,29 [48] | 1,0, [9] [18] 1,3, [10] 1,4 [48] | mg / dL | |||
Bilirubine directe / conjuguée | 0,0 [9] ou N / A [4] | 5, [9] 7 [4] [47] | μmol / L | ||
0 [9] [10] | 0,3, [9] [10] 0,4 [18] | mg / dL | |||
Alanine transaminase (ALAT / ALAT [4] ) | 5, [49] 7, [10] 8 [9] | 20, [9] 21, [13] 56 [10] | U / L | Aussi appelé sérum transaminase glutamique pyruvique(SGPT) | |
Femelle | 0,15 [4] | 0,75 [4] | μ kat / L | ||
Mâle | 0,15 [4] | 1,1 [4] | |||
Aspartate transaminase (AST / ASAT [4] ) | Femelle | 6 [50] | 34 [50] | IU / L | Aussi appelé transaminase glutamique oxaloacétique sérique (SGOT) |
0,25 [4] | 0,60 [4] | μ kat / L | |||
Mâle | 8 [50] | 40 [50] | IU / L | ||
0,25 [4] | 0,75 [4] | μ kat / L | |||
Phosphatase alcaline (ALP) | Femelle | 42 [49] | 98 [49] | U / L | |
Mâle | 53 [49] | 128 [49] | |||
( Activité enzymatique ) | 0,6 [4] | 1,8 [4] | μ kat / L | ||
Gamma glutamyl transférase (GGT) | 5, [49] 8 [10] | 40, [49] 78 [10] | U / L | ||
Femmes | 0,63 [51] | μ kat / L | |||
Hommes | 0,92 [51] | μ kat / L |
Tests cardiaques
Test | Type de patient | Limite inférieure | Limite supérieure | Unité | commentaires |
---|---|---|---|---|---|
Créatine kinase (CK) | mâle | 24, [52] 38, [10] 60 [49] | 174, [18] 320 [49] | U / L ou ng / mL |
|
0,42 [53] | 1,5 [53] | μkat / L | |||
femelle | 24, [52] 38, [10] 96 [18] | 140, [18] 200 [49] | U / L ou ng / mL |
||
0,17 [53] | 1,17 [53] | μkat / L | |||
CK-MB | 0 | 3, [10] 3,8, [4] 5 [49] | ng / mL ou μg / L [4] | ||
Myoglobine | Femelle | 1 [54] | 66 [54] | ng / mL ou μg / L | |
Mâle | 17 [54] | 106 [54] | |||
Troponine cardiaque T | 0,01 [55] | ng / mL | 99ème percentile |
Peptide natriurétique cérébral (BNP) | |
Interprétation | Plage / Cutoff |
---|---|
L’insuffisance cardiaque congestive improbable | < 100 pg / ml [56] [57] |
« Zone grise » | 100-500 pg / ml [56] [57] |
Insuffisance cardiaque congestive probable | > 500 pg / ml [56] [57] |
NT-proBNP | ||
Interprétation | Âge | Couper |
---|---|---|
Insuffisance cardiaque congestive probable | < 75 ans | > 125 pg / ml [58] |
> 75 ans | > 450pg / mL [58] |
Lipides
Test | Type de patient | Limite inférieure | Limite supérieure | Unité | Cible thérapeutique |
---|---|---|---|---|---|
Triglycérides | 10-39 ans | 54 [18] | 110 [18] | mg / dL | <100 mg / dL [59] ou 1,1 [59] mmol / L |
0,61 [60] | 1,2 [60] | mmol / L | |||
40-59 ans | 70 [18] | 150 [18] | mg / dL | ||
0,77 [60] | 1,7 [60] | mmol / L | |||
> 60 ans | 80 [18] | 150 [18] | mg / dL | ||
0,9 [60] | 1,7 [60] | mmol / L | |||
Cholestérol total | 3,0, [61] 3,6 [9] [61] | 5,0, [4] [62] 6,5 [9] | mmol / L | <3,9 [59] | |
120, [10] 140 [9] | 200, [10] 250 [9] | mg / dL | <150 [59] | ||
Cholestérol HDL | femelle | 1,0, [63] 1,2, [4] 1,3 [61] | 2,2 [63] | mmol / L | > 1,0 [63] ou 1,6 [61] mmol / L 40 [64] ou 60 [65] mg / dL |
40, [64] 50 [66] | 86 [64] | mg / dL | |||
Cholestérol HDL | mâle | 0,9 [4] [63] | 2,0 [63] | mmol / L | |
35 [64] | 80 [64] | mg / dL | |||
cholestérol LDL (Non valide lorsque triglycérides> 5,0 mmol / L) |
2,0, [63] 2,4 [62] | 3,0, [4] [62] 3,4 [63] | mmol / L | <2,5 [63] | |
80, [64] 94 [64] | 120, [64] 130 [64] | mg / dL | <100 [64] | ||
Quotient LDL / HDL | n / a | 5 [4] | (sans unité) |
Marqueurs tumoraux
Test | Couper | Unité | commentaires |
---|---|---|---|
Alpha foetoprotéine (AFP) | 44 [10] | ng / mL ou μg / L | Carcinome hépatocellulaire ou cancer des testicules |
Bêta gonadotrophine chorionique humaine (bHCG) | 5 [10] | IU / l ou mU / ml | chez les hommes et les femmes non enceintes |
CA19-9 | 40 [10] | U / ml | Cancer du pancréas |
CA-125 | 30, [67] 35 [68] | kU / L ou U / mL | |
Antigène carcino-embryonnaire (CEA) non-fumeurs à 50 ans |
3,4, [4] 3,6 [69] | μg / l | |
Antigène carcino-embryonnaire (CEA) non-fumeurs à 70 ans |
4,1 [69] | μg / l | |
Antigène carcino-embryonnaire (ACE) – fumeurs | 5 [70] | μg / l | |
Antigène spécifique de la prostate (PSA) | 2,5, [4] 4 [10] | μg / L [4] [10] ou ng / mL [18] | moins de 45 ans <2,5 μg / L |
BOUILLIE | 3 [18] | unités / dL (unités Bodansky) | |
Calcitonine | 5, [71] 15 [71] | ng / L ou pg / mL | Coupure contre le cancer médullaire de la thyroïde [71] |
Endocrinologie
Hormones thyroïdiennes
Test | Type de patient | Limite inférieure | Limite supérieure | Unité |
---|---|---|---|---|
Hormone stimulant la thyroïde (TSH ou thyrotropine) |
Adultes – gamme standard |
0,3, [4] 0,4, [10] 0,5, [18] 0,6 [72] | 4,0, [4] 4,5, [10] 6,0 [18] | mUI / L ou μIU / mL |
Adultes – gamme optimale |
0,3, [73] 0,5 [74] | 2,0, [74] 3,0 [73] | mUI / L ou μIU / mL | |
Nourrissons | 1,3 [75] | 19 [75] | mUI / L ou μIU / mL | |
Thyroxine libre (FT4) | Adulte normal | 0,7, [76] 0,8 [10] | 1,4, [76] 1,5, [10] 1,8 [77] | ng / dL |
9, [4] [78] 10, [79] 12 [80] | 18, [4] [78] 23 [80] | pmol / L | ||
Enfant / Adolescent 31 j – 18 ans |
0,8 [76] | 2,0 [76] | ng / dL | |
10 [78] | 26 [78] | pmol / L | ||
Enceinte | 0,5 [76] | 1,0 [76] | ng / dL | |
6,5 [78] | 13 [78] | pmol / L | ||
Thyroxine totale | 4, [79] 5,5 [10] | 11, [79] 12,3 [10] | μg / dL | |
60 [79] [80] | 140, [79] 160 [80] | nmol / L | ||
Triiodothyronine libre (FT3) | Adulte normal | 0,2 [79] | 0,5 [79] | ng / dL |
3.1 [81] | 7,7 [81] | pmol / L | ||
Enfants 2-16 ans | 0,1 [82] | 0,6 [82] | ng / dL | |
1,5 [81] | 9.2 [81] | pmol / L | ||
Triiodothyronine totale | 60, [10] 75 [79] | 175, [79] 181 [10] | ng / dL | |
0,9, [4] 1,1 [79] | 2,5, [4] 2,7 [79] | nmol / L | ||
Globuline liant la thyroxine (TBG) | 12 [10] | 30 [10] | mg / L | |
Thyroglobuline (Tg) | 1,5 [79] | 30 [79] | pmol / L | |
1 [79] | 20 [79] | μg / L |
Hormones sexuelles
Les diagrammes ci-dessous prennent en compte la variabilité inter-cycle et inter-femme dans l’affichage des intervalles de référence pour l’ estradiol , la progestérone , la FSH et la LH .
Test | Type de patient | Limite inférieure | Limite supérieure | Unité |
---|---|---|---|---|
Dihydrotestostérone | mâle adulte | 30 [84] | 85 [84] | ng / dL |
Testostérone | Homme, ensemble | 8, [85] 10 [86] | 27, [85] 35 [86] | nmol / L |
230, [87] 300 [88] | 780 [87] – 1000 [88] | ng / dL | ||
Homme <50 ans | 10 [4] | 45 [4] | nmol / L | |
290 [87] | 1300 [87] | ng / dL | ||
Homme> 50 ans | 6.2 [4] | 26 [4] | nmol / L | |
180 [87] | 740 [87] | ng / dL | ||
Femelle | 0,7 [86] | 2,8 [86] – 3,0 [4] | nmol / L | |
20 [88] | 80 [88] – 85 [87] | ng / dL | ||
17α-hydroxyprogestérone | mâle | 0,06 [18] | 3,0 [18] | mg / L |
0,18 [89] | 9.1 [89] | μmol / l | ||
Femme (phase folliculaire) | 0,2 [18] | 1,0 [18] | mg / L | |
0,6 [89] | 3,0 [89] | μmol / l | ||
Stimulant folliculaire hormone (FSH) |
Prépubère | <1 [90] | 3 [90] | IU / L |
Homme adulte | 1 [90] | 8 [90] | ||
Femelle adulte ( folliculaire et phase lutéale ) |
1 [90] | 11 [90] | ||
Femelle adulte ( Ovulation ) | 6 [90] 95% PI (standard) |
26 [90] 95% PI) |
||
5 [91] 90% PI (utilisé dans le schéma) |
15 [91] (90% PI) |
|||
Femelle post-ménopausée | 30 [90] | 118 [90] | ||
Hormone lutéinisante (LH) | Femme, pic | 20 [91] 90% PI (utilisé dans le schéma) |
75 [91] (90% PI) |
IU / L |
Femme, post-ménopausée | 15 [92] | 60 [92] | ||
Homme âgé de 18 ans et plus | 2 [93] | 9 [93] | ||
Estradiol (un oestrogène ) |
Homme adulte | 50 [94] | 200 [94] | pmol / L |
14 [95] | 55 [95] | pg / mL | ||
Femelle adulte (jour 5 de la phase folliculaire , et phase lutéale ) |
70 [94] | 500, [94] 600 [94] | pmol / L | |
19 [95] | 140, [95] 160 [95] | pg / mL | ||
Femelle adulte – libre (non lié aux protéines) | 0,5 [96] | 9 [96] | pg / mL | |
1,7 [96] | 33 [96] | pmol / L | ||
Femelle post-ménopausée | N / A [94] | <130 [94] | pmol / L | |
N / A [95] | <35 [95] | pg / mL | ||
Progestérone | Femelle en phase médio- lutéale (jour 21-23) | 17, [91] 35 [97] | 92 [97] | nmol / L |
6, [91] 11 [98] | 29 [98] | ng / mL | ||
Androstenedione | Adulte mâle et femelle | 60 [92] | 270 [92] | ng / dL |
Femelle post-ménopausée | <180 [92] | |||
Prépubère | <60 [92] | |||
Sulfate de déhydroépiandrostérone | Adulte mâle et femelle | 30 [99] | 400 [99] | μg / dL |
SHBG | Femelle adulte | 40 [100] | 120 [100] | nmol / L |
Homme adulte | 20 [100] | 60 [100] | ||
Hormone anti-Müllérienne (AMH) | 13-45 ans | 0,7 [101] | 20 [101] | ng / mL |
5 [102] | 140 [102] | pmol / l |
D’autres hormones
Test | Type de patient | Limite inférieure | Limite supérieure | Unité |
---|---|---|---|---|
Hormone adrénocorticotrope (ACTH) | 4,4 [103] | 18, [104] 22 [103] | pmol / L | |
20 [10] | 80, [105] 100 [10] | pg / mL | ||
Cortisol | 09h00 | 140 [106] | 700 [106] | nmol / L |
5 [107] | 25 [107] | μg / dL | ||
Minuit | 80 [106] | 350 [106] | nmol / L | |
2,9 [107] | 13 [107] | μg / dL | ||
Hormone de croissance (jeûne) | 0 | 5 [9] | ng / mL | |
Hormone de croissance ( stimulation à l’arginine ) | 7 [9] | n / a | ng / mL | |
IGF-1 | Femme, 20 ans | 110 [108] | 420 [108] | ng / mL |
Femme, 75 ans | 55 [108] | 220 [108] | ||
Homme, 20 ans | 160 [108] | 390 [108] | ||
Homme, 75 ans | 48 [108] | 200 [108] | ||
Prolactine | Femelle | 71, [109] 105 [109] | 348, [109] 548 [109] | mUI / L |
3,4, [109] 3,9 [109] | 16,4, [109] 20,3 [109] | μg / L | ||
Mâle | 58, [109] 89 [109] | 277, [109] 365 [109] | mUI / L | |
2,7, [109] 3,3 [109] | 13,0, [109] 13,5 [109] | μg / L | ||
Hormone parathyroïdienne (PTH) | 10, [110] 17 [111] | 65, [110] 70 [111] | pg / mL | |
1,1, [4] 1,8 [112] | 6,9, [4] 7,5 [112] | pmol / L | ||
25-hydroxycholécalciférol (une vitamine D ) – Plage de référence standard |
8, [18] [113] 9 [113] | 40, [113] 80 [18] | ng / mL | |
20, [114] 23 [115] | 95, [115] 150 [114] | nmol / L | ||
25-hydroxycholécalciférol – Plage cible thérapeutique |
30, [116] 40 [117] | 65, [117] 100 [116] | ng / mL | |
85, [59] 100 [117] | 120, [59] 160 [117] | nmol / L | ||
Activité rénine plasmatique | 0,29, [118] 1,9 [119] | 3,7 [118] [119] | ng / (mL * heure) | |
3,3, [120] 21 [121] | 41 [120] [121] | mcU / mL | ||
Aldostérone | Adulte | 19, [120] 34,0 [120] | ng / dL | |
530, [122] 940 [122] | pmol / L | |||
Rapport aldostérone-rénine | Adulte | 13,1, [123] 35,0 [123] | ng / dl par ng / (mL · h) | |
360, [123] 970 [123] | pmol / litre par μg / (L · h) |
Vitamines
Test | Type de patient | Gamme standard | Unité | Gamme optimale | ||
---|---|---|---|---|---|---|
Limite inférieure | Limite supérieure | Limite inférieure | Limite supérieure | |||
Vitamine A | 30 [18] | 65 [18] | μg / dL | |||
Vitamine B 9 (Acide folique / Folate) – Sérum |
Âge> 1 an | 3,0 [124] | 16 [124] | ng / mL ou μg / L | 5 [125] | |
6,8 [126] | 36 [126] | nmol / l | 11 [126] | |||
Vitamine B 9 (Acide folique / Folate) – Globules rouges |
200 [124] | 600 [124] | ng / mL ou μg / L | |||
450 [126] | 1400 [126] | nmol / L | ||||
Enceinte | ng / mL ou μg / L | 400 [124] | ||||
nmol / L | 900 [124] | |||||
Vitamine B 12 (Cobalamine) | 130, [127] 160 [128] | 700, [127] 950 [128] | ng / L | |||
100, [129] 120 [4] | 520, [129] 700 [4] | pmol / L | ||||
Homocystéine | 3,3, [130] 5,9 [130] | 7,2, [130] 15,3 [130] | μmol / L | 6,3 [59] | ||
45, [131] 80 [131] | 100, [131] 210 [131] | μg / dL | 85 [59] | |||
Vitamine C (acide ascorbique) | 0,4 [18] | 1,5 [18] | mg / dL | 0,9 [59] | ||
23 [132] | 85 [132] | μmol / L | 50 [59] | |||
25-hydroxycholécalciférol (une vitamine D ) | 8, [18] [113] 9 [113] | 40, [113] 80 [18] | ng / mL | 30, [116] 40 [117] | 65, [117] 100 [116] | |
20, [114] 23 [115] | 95, [115] 150 [114] | nmol / L | 85, [59] 100 [117] | 120, [59] 160 [117] | ||
Vitamine E | μmol / L | 28 [59] | ||||
mg / dL | 1,2 [59] |
Toxines
Test | Type de limite | Limite | Unité |
---|---|---|---|
Plomb | Gamme de santé optimale | <20 [13] ou 40 [18] | μg / dL |
Teneur en éthanol dans le sang | Limite de conduite en état d’ébriété | 0, [133] 0,2, [133] 0,8 [133] | ‰ ou g / L |
17,4 [134] | mmol / L |
Hématologie
Globules rouges
Ces valeurs (à l’exception de l’ hémoglobine dans le plasma ) concernent le sang total et non seulement le plasma sanguin.
Test | Patient | Limite inférieure | Limite supérieure | Unité | commentaires |
---|---|---|---|---|---|
Hémoglobine (Hb) | mâle | 2,0, [135] 2,1 [9] [136] | 2,5, [135] 2,7 [9] [136] | mmol / L | Plus élevé chez les nouveau – nés , plus faible chez les enfants. |
130, [4] 132, [10]135 [9] | 162, [10] 170, [4] 175 [9] | g / L | |||
femelle | 1,8, [135] 1,9 [9] [136] | 2,3, [135] 2,5 [9] [135][136] | mmol / L | Différence de sexe négligeable jusqu’à l’âge adulte. | |
120 [4] [9] [10] | 150, [4] 152, [10] 160 [9] [18] | g / L | |||
Sous-unités de l’hémoglobine (parfois simplement affichées comme « hémoglobine ») | mâle | 8,0, [137] 8,4 [137] | 10,0, [137] 10,8 [137] | mmol / L | 4 par molécule d’hémoglobine |
femelle | 7.2, [137] 7,6 [137] | 9.2, [137] 10.0 [137] | |||
Hémoglobine dans le plasma | 0,16 [9] | 0,62 [9] | μmol / L | Normalement diminutif par rapport aux globules rouges à l’intérieur | |
1 | 4 | mg / dL | |||
Hémoglobine glyquée (Hb A1c ) | <50 ans | 3,6 [4] | 5,0 [4] | % de Hb | |
> 50 ans | 3,9 [4] | 5.3 [4] | |||
Haptoglobine | <50 ans | 0,35 [4] | 1,9 [4] | g / L | |
> 50 ans | 0,47 [4] | 2,1 [4] | |||
Hématocrite (Hct) | mâle | 0,39, [4] 0,4, [10]0,41, [9] 0,45 [18] | 0,50, [4] 0,52, [10]0,53, [9] 0,62 [18] | ||
femelle | 0,35, [4] 0,36, [9]0,37 [10] [18] | 0,46, [4] [9] [10] 0,48 [18] | |||
Enfant | 0,31 [10] | 0,43 [10] | |||
Volume cellulaire moyen (MCV) | Mâle | 76, [18] 82 [10] | 100, [18] 102 [10] | fL | Les cellules sont plus grandes chez les nouveau – nés , mais plus petites chez les autres enfants. |
Femelle | 78 [10] | 101 [10] | fL | ||
Largeur de distribution des globules rouges (RDW) | 11,5 [10] | 14,5 [10] | % | ||
Hémoglobine cellulaire moyenne (MCH) | 0,39 [9] | 0,54 [9] | fmol / cellule | ||
25, [9] 27 [4] [18] | 32, [18] 33, [4] 35 [9] | pg / cellule | |||
Concentration moyenne d’hémoglobine corpusculaire (MCHC) | 31, [10] 32 [4] [18] | 35, [10] 36 [4] [18] | g / dL ou% [note 1] | ||
4,8, [138] 5,0 [138] | 5,4, [138] 5,6 [138] | mmol / L | |||
Erythrocytes / Globules rouges (RBC) | mâle | 4,2, [18] 4,3 [4] [9][10] | 5,7, [4] 5,9, [9] 6,2, [10] 6,9 [18] | x10 12 / L ou mln / mm 3 |
|
Femelle | 3,5, [9] 3,8, [10] 3,9 [4] | 5,1, [4] 5,5 [9] [10] | |||
Enfant / Enfant | 3,8 [10] | 5,5 [10] | |||
Les réticulocytes | Adulte | 26 [4] | 130 [4] | x10 9 / L | |
Adulte | 0,5 [9] [10] | 1,5 [9] [10] | % de RBC | ||
Nouveau née | 1,1 [10] | 4,5 [10] | % de RBC | ||
Bébé | 0,5 [10] | 3,1 [10] | % de RBC |
Globules blancs
Ces valeurs sont pour le sang total et pas seulement pour le plasma sanguin.
Test | Type de patient | Limite inférieure | Limite supérieure | Unité |
---|---|---|---|---|
Nombre de globules blancs ( WBC ) | Adulte | 3,5, [4] 3,9, [139] 4,1, [10] 4,5 [9] | 9,0, [4] 10,0, [139] 10,9, [10] 11 [9] |
|
Nouveau née | 9 [140] | 30 [140] | ||
1 an | 6 [140] | 18 [140] | ||
Granulocytes neutrophiles (Grans AKA, polys, PMN, ou segs) |
Adulte | 1,3, [4] 1,8, [139] 2 [140] | 5.4, [4] 7, [139] 8 [140] | x10 9 / L |
45-54 [9] | 62, [9] 74 | % de WBC | ||
Nouveau née | 6 [140] | 26 [140] | x10 9 / L | |
Formes de bandes neutrophiles | Adulte | 0,7 [140] | x10 9 / L | |
3 [9] | 5 [9] | % de WBC | ||
Lymphocytes | Adulte | 0,7, [4] 1,0 [139] [140] | 3,5, [139] 3,9, [4] 4,8 [140] | x10 9 / L |
16-25 [9] | 33, [9] 45 | % de WBC | ||
Nouveau née | 2 [140] | 11 [140] | x10 9 / L | |
Monocytes | Adulte | 0,1, [4] 0,2 [141] [142] | 0,8 [4] [140] [142] | x10 9 / L |
3, [9] 4,0 | 7, [9] 10 | % de WBC | ||
Nouveau née | 0,4 [140] | 3,1 [140] | x10 9 / L | |
Leucocytes mononucléaires (Lymphocytes + monocytes) |
Adulte | 1,5 | 5 | x10 9 / L |
20 | 35 | % de WBC | ||
Cellules T CD4 + | Adulte | 0,4, [10] 0,5 [13] | 1,5, [13] 1,8 [10] | x10 9 / L |
Granulocytes éosinophiles | Adulte | 0,0, [4] 0,04 [142] | 0,44, [142] 0,45, [140] 0,5 [4] | x10 9 / L |
1 [9] | 3, [9] 7 | % de WBC | ||
Nouveau née | 0,02 [140] | 0,85 [140] | x10 9 / L | |
Granulocytes basophiles | Adulte | 40 [139] | 100, [4] [142] 200, [140] 900 [139] | x10 6 / L |
0.0 | 0,75, [9] 2 | % de WBC | ||
Nouveau née | 0,64 [140] | x10 9 / L |
Coagulation
Test | Limite inférieure | Limite supérieure | Unité | commentaires |
---|---|---|---|---|
Thrombocyte / nombre de plaquettes (Plt) | 140, [10] 150 [4] [9] | 350, [4] [18] 400, [9] 450 [10] | x10 9 / L ou x1000 / μL |
|
Volume moyen des plaquettes (MPV) | 7.2, [143] 7.4, [144] 7.5 [145] | 10,4, [144] 11,5, [145] 11,7 [143] | fL | |
Temps de prothrombine (PT) | 10, [13] 11, [9] [146] 12 [10] | 13, [13] 13,5, [146] 14, [10]15 [9] | s | La référence de PT varie entre les kits de laboratoire – INR est standardisé |
INR | 0,9 [4] | 1,2 [4] | L’INR est un rapport corrigé du PT d’un patient à la normale | |
Activé temps de thromboplastine partielle(APTT) | 18, [10] 30 [4] [13] | 28, [10] 42, [4] 45 [13] | s | |
Temps de thrombine (TCT) | 11 | 18 | s | |
fibrinogène | 1,7, [10] 2,0 [4] | 3,6, [4] 4,2 [10] | g / L | |
antithrombine | 0,80 [4] | 1.2 [4] | kIU / L | |
0,15, [147] 0,17 [148] | 0,2, [147] 0,39 [148] | mg / mL | ||
Temps de saignement | 2 | 9 | minutes | |
Viscosité | 1,5 [149] | 1,72 [149] | cP |
Immunologie
Protéines de phase aiguë
Protéines de la phase aiguë sont des marqueurs de l’inflammation .
Test | Patient | Limite inférieure | Limite supérieure | Unité | commentaires |
---|---|---|---|---|---|
La vitesse de sédimentation érythrocytaire (ESR) |
Mâle | 0 | Age ÷ 2 [150] | mm / h | ESR augmente avec l’ âge et a tendance à être plus élevé chez lesfemmes. [151] |
Femelle | (Age + 10) ÷ 2[150] | ||||
La protéine C-réactive (CRP) | 5, [4] [152] 6 [153] | mg / L | |||
200, [154] 240[154] | nmol / L | ||||
Alpha 1-antitrypsine (AAT) | 20, [155] 22 [156] | 38, [156] 53 [155] | umol / L | ||
89, [157] 97 [4] | 170, [4] 230 [157] | mg / dL | |||
procalcitonine | 0,15 [158] | ng / ml ou mg / L |
Isotypes d’anticorps
Test | Patient | Limite inférieure | Limite supérieure | Unité |
---|---|---|---|---|
IgA | Adulte | 70, [4] 110 [159] | 360, [4] 560 [159] | mg / dL |
IgD | 0,5 [159] | 3.0 [159] | ||
IgE | 0,01 [159] | 0,04 [159] | ||
IgG | 800 [159] | 1800 [159] | ||
IgM | 54 [159] | 220 [159] |
Auto – anticorps
Test | Négatif | Équivoque | Positif | Unité |
---|---|---|---|---|
anti-SS-A (Ro) | <15 [161] | 15-25 [161] | > 25 [161] | Unités par millilitre (U / mL) |
anti-SS-B (La) | <3 [161] | 3-4 [161] | > 4 [161] | |
Anti ds-ADN | <40 [161] | 40-60 [161] | > 60 [161] | |
Anti-ADN ss | <8 [161] | 8-10 [161] | > 10 [161] | |
Les anticorps anti-histones | <25 [161] | n / a [161] | > 25 [161] | |
Cytoplasmiques / classiques cytoplasmiques anti-neutrophiles anticorps (c-ANCA) |
<20 [161] | 21-30 [161] | > 30 [161] | |
Périnucléaires cytoplasmiques anti-neutrophiles anticorps (p-ANCA) |
<5 [161] | n / a | > 5 [161] | |
Les anticorps anti-mitochondrial (AMA) | <10 [161] | n / a [161] | > 10 [161] | |
Le facteur rhumatoïde (RF) | <20 | 20-30 | > 30 [10] | |
Antistreptolysine O titre (ASOT) en âge préscolaire |
> 100 | |||
ASOT à l’âge scolaire | > 250 [10] | |||
ASOT chez les adultes | > 125 [10] |
Test | Négatif | positif faible / faible | modéré positif | positif élevé / fort | Unité |
---|---|---|---|---|---|
Antiphospholipides IgG | <20 [161] | 20-30 [161] | 31-50 [161] | > 51 [161] | GPLU / ml [161] |
IgM anti-phospholipides | <1,5 [161] | 01.05 à 02.05 [161] | 2 à 9,9 [161] | > 10 [161] | MPL / ml [161] |
IgA anti-phospholipides | <10 [161] | 10-20 [161] | 21-30 [161] | > 31 [161] | arb U / ml [161] |
anticorps anti-protéine citrullinés | <20 [161] | 20-39 [161] | 40-59 [161] | > 60 [161] | UE [161] |
Autre immunologie
Test | Limite inférieure | Limite supérieure | Unité |
---|---|---|---|
Sérum chaînes légères libres (FLC): rapport kappa / lambda | 0,26 [162] | 1,65 [162] | (Unité inférieure) |
D’ autres enzymes et protéines
Test | Limite inférieure | Limite supérieure | Unité | commentaires |
---|---|---|---|---|
protéinémie | 60, [9] 63 [10] | 78, [9] 82, [10] 84 [18] | g / L | |
La lactate déshydrogénase (LDH) | 50 [18] | 150 [18] | U / L | |
0,4 [49] | 1.7 [49] | umol / L | ||
1.8 [4] | 3.4 [4] | μ kat / L | <70 ans [4] | |
amylases | 25, [9] 30, [10] 53[18] | 110, [10] 120, [163] 123, [18] 125, [9]190 [49] | U / L | |
0,15 [4] | 1.1 [4] | μ kat / L | ||
200 [154] | 240 [154] | nmol / L | ||
D-dimère | n / a | 500 [164] | ng / mL | Supérieur chez les femmes enceintes [165] |
0,5 [4] | mg / L | |||
Lipase | 7, [10] 10, [18] 23[49] | 60, [10] 150, [18] 208 [49] | U / L | |
L’ enzyme de conversion de l’ angiotensine(ACE) | 23 [49] | 57 [49] | U / L | |
phosphatase acide | 3.0 [49] | ng / mL | ||
Protéine cationique des éosinophiles (ECP) | 2.3 [4] | 16 [4] | ug / L |
D’ autres électrolytes et des métabolites
Test | type de patient | Limite inférieure | Limite supérieure | Unité | commentaires |
---|---|---|---|---|---|
osmolalité | 275, [9] 280, [18] 281 [4] | 295, [9] 296, [18] 297 [4] | mOsm / kg | poids Plasma exclut solutés | |
osmolarité | Un peu moins de osmolalité | mOsm / l | volume de plasma comprend solutés | ||
Urée | 3.0 [166] | 7.0 [166] | mmol / L | BUN – azote uréique du sang | |
7 [9] | 18, [9] 21 [10] | mg / dL | |||
* L’ acide urique [10] | 0,18 [9] | 0,48 [9] | mmol / L | ||
Femelle | 2,0 [18] | 7,0 [18] | mg / dL | ||
Mâle | 2.1 [18] | 8,5 [18] | mg / dL | ||
Créatinine | mâle | 60, [4] 68 [167] | 90, [4] 118 [167] | umol / L | Peut être complété par la clairance de la créatinine |
0,7, [168] 0,8 [168] | 1.0, [168] 1.3 [168] | mg / dL | |||
femelle | 50, [4] 68 [167] | 90, [4] 98 [167] | umol / L | ||
0,6, [168] 0,8 [168] | 1.0, [168] 1.1 [168] | mg / dL | |||
Ratio BUN / Créatinine | 5 [18] | 35 [18] | – | ||
Plasma glucose ( à jeun) | 3.8, [9] 4.0 [4] | 6.0, [4] 6.1 [169] | mmol / L | Voir aussi l’ hémoglobine glyquée (en hématologie) | |
65, [10] 70, [9] 72 [170] | 100, [169] 110 [18] | mg / dL | |||
glucose dans le sang complet (à jeun) | 3.3 [4] | 5.6 [4] | mmol / L | ||
60 [170] | 100 [170] | mg / dL | |||
glucose aléatoire | 3.9 [171] | 7.8 [171] | mmol / L | ||
70 [172] | 140 [172] | mg / dL | |||
Lactate (veineuses) | 4,5 [18] | 19,8 [18] | mg / dL | ||
0,5 [173] | 2.2 [173] | mmol / L | |||
Lactate (Arterial) | 4,5 [18] | 14,4 [18] | mg / dL | ||
0,5 [173] | 1,6 [173] | mmol / L | |||
Pyruvate | 300 [18] | 900 [18] | ug / dL | ||
34 [174] | 102 [174] | umol / L | |||
cétones | 1 [175] | mg / dL | |||
0,1 [175] | mmol / L |
Médicaments
Test | Limite inférieure | Limite supérieure | Unité | commentaires |
---|---|---|---|---|
digoxine | 0,5 [176] | 2,0 [176] | ng / ml | Étroite fenêtre thérapeutique |
0,6 [176] | 2.6 [176] | nmol / l | ||
Lithium | 0,4, [177] 0,5 [178] [179] 0,8 [180] | 1.3 [178] [179] | mmol / l | Étroite fenêtre thérapeutique |
paracétamol | 30 [181] | mg / L | Risque de toxicité du paracétamol à des niveaux plus élevés | |
200 [181] | umol / L |
Références
- range list from Uppsala University Hospital (« Laborationslista »). Artnr 40284 Sj74a. Issued on April 22, 2008
- ^ Jump up to:a b c Arterial versus venous reference ranges – Brief Article Medical Laboratory Observer, April, 2000 by D. Robert Dufour
- Jump up^ Abbassi-Ghanavati, M.; Greer, L. G.; Cunningham, F. G. (2009). « Pregnancy and Laboratory Studies ». Obstetrics & Gynecology. 114 (6): 1326. doi:10.1097/AOG.0b013e3181c2bde8.
- Jump up^ Armbruster, David; Miller (August 2007). « The Joint Committee for Traceability in Laboratory Medicine (JCTLM): A Global Approach to Promote the Standardisation of Clinical Laboratory Test Results ». The Clinical Biochemist Reviews. 28 (3): 105–14. PMC 1994110 . PMID 17909615.
- Jump up^ PROOPIOMELANOCORTIN; NCBI –> POMC Retrieved on September 28, 2009
- ^ Jump up to:a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar asat au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl bm bn bo bp bq br bs bt bu bv bw bx by bz cacb cc cd ce cf cg ch ci cj ck cl cm cn co cp cq cr cs ct cu cv cw cx cy cz da db dc dd Last page of Deepak A. Rao; Le, Tao; Bhushan, Vikas (2007). First Aid for the USMLE Step 1 2008 (First Aid for the Usmle Step 1). McGraw-Hill Medical. ISBN 0-07-149868-0.
- ^ Jump up to:a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar asat au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl bm bn bo bp bq br bs bt bu bv bw bx by bz cacb cc cd ce cf cg ch ci cj ck cl cm cn co cp cq cr cs ct cu cv cw cx cy cz da db dc Normal Reference Range Table Archived 2011-12-25 at the Wayback Machine. from The University of Texas Southwestern Medical Center at Dallas. Used in Interactive Case Study Companion to Pathologic basis of disease.
- ^ Jump up to:a b c d Derived from molar values using molar mass of 22.99 g•mol−1
- ^ Jump up to:a b Derived from molar values using molar mass of 39.10 g•mol−1
- ^ Jump up to:a b c d e f g h i j k l m MERCK MANUALS > Common Medical Tests > Blood Tests Last full review/revision February 2003
- ^ Jump up to:a b Derived from molar values using molar mass of 35.45 g•mol−1
- ^ Jump up to:a b Larsson L, Ohman S (November 1978). « Serum ionized calcium and corrected total calcium in borderline hyperparathyroidism ». Clin. Chem. 24 (11): 1962–65. PMID 709830.
- ^ Jump up to:a b c d Derived from molar values using molar mass of 40.08 g•mol−1
- ^ Jump up to:a b c Derived from mass values using molar mass of 40.08 g•mol−1
- ^ Jump up to:a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar asat au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl bm bn bo bp bq br bs bt bu bv bw bx by bzBlood Test Results – Normal Ranges Bloodbook.Com
- ^ Jump up to:a b c d e f g h i j k l Slon S (2006-09-22). « Serum Iron ». University of Illinois Medical Center. Retrieved 2006-07-06.
- ^ Jump up to:a b c d Diagnostic Chemicals Limited > Serum Iron-SL Assay July 15, 2005
- ^ Jump up to:a b c d e f g h i j k l m Derived from mass values using molar mass of 55.85 g•mol−1
- ^ Jump up to:a b Table 1. Page 133″ Clinical Chemistry 45, No. 1, 1999 (stating 1.9–3.3 g/L)
- ^ Jump up to:a b Derived by dividing mass values with molar mass
- ^ Jump up to:a b c d Ferritin by: Mark Levin, MD, Hematologist and Oncologist, Newark, NJ. Review provided by VeriMed Healthcare Network
- ^ Jump up to:a b Andrea Duchini. « Hemochromatosis Workup ». Medscape. Retrieved 2016-07-14.Updated: Jan 02, 2016
- ^ Jump up to:a b c d e Derived from mass values using molar mass of 450,000 g•mol−1
- ^ Jump up to:a b Mitchell ML, Filippone MD, Wozniak TF (August 2001). « Metastatic carcinomatous cirrhosis and hepatic hemosiderosis in a patient heterozygous for the H63D genotype ». Arch. Pathol. Lab. Med. 125 (8): 1084–7. doi:10.1043/0003-9985(2001)125<1084:MCCAHH>2.0.CO;2 (inactive 2018-02-06). PMID 11473464.
- ^ Jump up to:a b Diaz J, Tornel PL, Martinez P (July 1995). « Reference intervals for blood ammonia in healthy subjects, determined by microdiffusion ». Clin. Chem. 41 (7): 1048. PMID 7600690.
- ^ Jump up to:a b c d Derived from molar values using molar mass of 17.03 g/mol
- ^ Jump up to:a b Derived from mass values using molar mass of 63.55 g•mol−1
- Jump up^ « Reference range for copper ». GPnotebook.
- ^ Jump up to:a b Derived from mass using molar mass of 151kDa
- Jump up^ Walter F. Boron (2005). Medical Physiology: A Cellular And Molecular Approaoch. Elsevier/Saunders. ISBN 1-4160-2328-3. Page 849
- ^ Jump up to:a b http://www.dlolab.com/PDFs/DLO-OCTOBER-2008-LAB-UPDATE.pdf
- ^ Jump up to:a b Derived from molar values using molar mass of 65.38 g/mol
- ^ Jump up to:a b Derived from mass values using molar mass of 65.38 g/mol
- ^ Jump up to:a b Derived from molar values using molar mass of 24.31 g/mol
- ^ Jump up to:a b Derived from mass values using molar mass of 24.31 g/mol
- Jump up^ Middleton P, Kelly AM, Brown J, Robertson M (August 2006). « Agreements between arterial and central venous values for pH, bicarbonate, base excess, and lactate ». Emerg Med J. 23 (8): 622–24. doi:10.1136/emj.2006.035915. PMC 2564165 . PMID 16858095.
- ^ Jump up to:a b c d e f g h i j k l The Medical Education Division of the Brookside Associates–> ABG (Arterial Blood Gas) Retrieved on Dec 6, 2009
- ^ Jump up to:a b Derived from molar values using molar mass of 1.01 g•mol−1
- ^ Jump up to:a b c d e f g h Derived from mmHg values using 0.133322 kPa/mmHg
- ^ Jump up to:a b Derived from molar values using molar mass of 44.010 g/mol
- ^ Jump up to:a b c d Derived from molar values using molar mass of 61 g/mol
- Jump up^ « Reference range (albumin) ». GPnotebook.
- ^ Jump up to:a b Derived from mass using molecular weight of 65kD
- ^ Jump up to:a b c d e Derived from mass values using molar mass of 585g/mol
- ^ Jump up to:a b Derived from molar values using molar mass of 585g/mol
- ^ Jump up to:a b c d e f g h i j k l m n o p q r s Fachwörterbuch Kompakt Medizin E-D/D-E. Author: Fritz-Jürgen Nöhring. Edition 2. Publisher:Elsevier, Urban&FischerVerlag, 2004. ISBN 3-437-15120-7, ISBN 978-3-437-15120-0. Length: 1288 pages
- ^ Jump up to:a b c d GPnotebook > reference range (AST) Retrieved on Dec 7, 2009
- ^ Jump up to:a b « Gamma-GT ». Leistungsverzeichnis. Medizinisch-Diagnostische Institute. Archived from the original on 25 April 2012. Retrieved 20 November 2011.
- ^ Jump up to:a b « Creatine kinase ». GPnotebook.
- ^ Jump up to:a b c d Page 585 in: Lee, Mary Ann (2009). Basic Skills in Interpreting Laboratory Data. Amer Soc of Health System. ISBN 1-58528-180-8.
- ^ Jump up to:a b c d Muscle Information and Courses from MediaLab, Inc. > Cardiac BiomarkersRetrieved on April 22, 2010
- Jump up^ Ashvarya Mangla. « Troponins ». medscape. Retrieved 2017-07-24. Updated: Jan 14, 2015
- ^ Jump up to:a b c Brenden CK, Hollander JE, Guss D, et al. (May 2006). « Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study ». American Heart Journal. 151 (5): 1006–11. doi:10.1016/j.ahj.2005.10.017. PMID 16644322.
- ^ Jump up to:a b c Strunk A, Bhalla V, Clopton P, et al. (January 2006). « Impact of the history of congestive heart failure on the utility of B-type natriuretic peptide in the emergency diagnosis of heart failure: results from the Breathing Not Properly Multinational Study ». The American Journal of Medicine. 119 (1): 69.e1–11. doi:10.1016/j.amjmed.2005.04.029. PMID 16431187.
- ^ Jump up to:a b Page 220 in: Lee, Mary Ann (2009). Basic Skills in Interpreting Laboratory Data. Amer Soc of Health System. ISBN 1-58528-180-8.
- ^ Jump up to:a b c d e f g h i j k l m n Adëeva Nutritionals Canada > Optimal blood test valuesRetrieved on July 9, 2009
- ^ Jump up to:a b c d e f Derived from values in mg/dl to mmol/l, by dividing by 89, according to faqs.org: What are mg/dl and mmol/l? How to convert? Glucose? Cholesterol? Last Update July 21, 2009. Retrieved on July 21, 2009
- ^ Jump up to:a b c d Derived from values in mg/dl to mmol/l, using molar mass of 386.65 g/mol
- ^ Jump up to:a b c « Reference range (cholesterol) ». GPnotebook.
- ^ Jump up to:a b c d e f g h Royal College of Pathologists of Australasia; Cholesterol (HDL and LDL) – plasma or serum Last Updated: Monday, 6 August 2007
- ^ Jump up to:a b c d e f g h i j Derived from values in mmol/l, using molar mass of 386.65 g/mol
- Jump up^ What Your Cholesterol Levels Mean. American Heart Association. Retrieved on September 12, 2009
- Jump up^ American Association for Clinical Chemistry; HDL Cholesterol
- Jump up^ GP Notebook > range (reference, ca-125) Retrieved on Jan 5, 2009
- Jump up^ ClinLab Navigator > Test Interpretations > CA-125 Retrieved on March 8, 2011
- ^ Jump up to:a b Bjerner J, Høgetveit A, Wold Akselberg K, et al. (June 2008). « Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study ». Scandinavian Journal of Clinical and Laboratory Investigation. 68 (8): 1–12. doi:10.1080/00365510802126836. PMID 18609108.
- Jump up^ Carcinoembryonic Antigen(CEA) at MedicineNet
- ^ Jump up to:a b c Basuyau JP, Mallet E, Leroy M, Brunelle P (October 2004). « Reference intervals for serum calcitonin in men, women, and children ». Clinical Chemistry. 50 (10): 1828–30. doi:10.1373/clinchem.2003.026963. PMID 15388660.
- Jump up^ The TSH Reference Range Wars: What’s « Normal? », Who is Wrong, Who is Right… By Mary Shomon, About.com. Updated: June 19, 2006. About.com Health’s Disease and Condition
- ^ Jump up to:a b 2006 Press releases: Thyroid Imbalance? Target Your Numbers Contacts: Bryan Campbell American] Association of Clinical Endocrinologists
- ^ Jump up to:a b The TSH Reference Range Wars: What’s « Normal? », Who is Wrong, Who is Right…By Mary Shomon, About.com. Updated: June 19, 2006
- ^ Jump up to:a b Demers, Laurence M.; Carole A. Spencer (2002). « LMPG: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease ». National Academy of Clinical Biochemistry(USA). Retrieved 2007-04-13. – see Section 2. Pre-analytic factors
- ^ Jump up to:a b c d e f Free T4; Thyroxine, Free; T4, Free UNC Health Care System
- Jump up^ Derived from molar values using molar mass of 776.87 g/mol
- ^ Jump up to:a b c d e f Derived from mass values using molar mass of 776.87 g/mol
- ^ Jump up to:a b c d e f g h i j k l m n o Table 4: Typical reference ranges for serum assays Archived2011-07-01 at the Wayback Machine. – Thyroid Disease Manager
- ^ Jump up to:a b c d van der Watt G, Haarburger D, Berman P (July 2008). « Euthyroid patient with elevated serum free thyroxine ». Clinical Chemistry. 54 (7): 1239–41. doi:10.1373/clinchem.2007.101428. PMID 18593963.
- ^ Jump up to:a b c d Derived from mass values using molar mass of 650.98 g/mol
- ^ Jump up to:a b Cioffi M, Gazzerro P, Vietri MT, et al. (2001). « Serum concentration of free T3, free T4 and TSH in healthy children ». Journal of Pediatric Endocrinology & Metabolism. 14 (9): 1635–9. doi:10.1515/jpem.2001.14.9.1635. PMID 11795654. INIST:13391788.
- Jump up^ Häggström, Mikael (2014). « Reference ranges for estradiol, progesterone, luteinizing hormone and follicle-stimulating hormone during the menstrual cycle ». WikiJournal of Medicine. 1 (1). doi:10.15347/wjm/2014.001.
- ^ Jump up to:a b Life Extension Foundation > Blood Testing Protocols
- ^ Jump up to:a b Andrology Australia: Your Health > Low Testosterone > Diagnosis
- ^ Jump up to:a b c d Derived from mass values using molar mass of 288.42g/mol
- ^ Jump up to:a b c d e f g Derived from molar values using molar mass of 288.42g/mol
- ^ Jump up to:a b c d MedlinePlus > Testosterone Update Date: 3/18/2008. Updated by: Elizabeth H. Holt, MD, PhD, Yale University. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director
- ^ Jump up to:a b c d Derived from mass values using molar mass of 330.46g/mol
- ^ Jump up to:a b c d e f g h i j reference range (FSH) GPnotebook. Retrieved on September 27, 2009
- ^ Jump up to:a b c d e f Values taken from day 1 after LH surge in: Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P, Stricker R (2006). « Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer ». Clinical Chemistry and Laboratory Medicine. 44 (7): 883–87. doi:10.1515/CCLM.2006.160. PMID 16776638.
- ^ Jump up to:a b c d e f New York Hospital Queens > Services and Facilities > Patient Testing > Pathology > New York Hospital Queens Diagnostic Laboratories > Test Directory > Reference Ranges Retrieved on Nov 8, 2009
- ^ Jump up to:a b Mayo Medical Laboratories > Test ID: LH, Luteinizing Hormone (LH), Serum, retrieved December 2012
- ^ Jump up to:a b c d e f g GPNotebook – reference range (oestradiol) Retrieved on September 27, 2009
- ^ Jump up to:a b c d e f g Derived from molar values using molar mass of 272.38g/mol
- ^ Jump up to:a b c d Total amount multiplied by 0.022 according to 2.2% presented in: Wu CH, Motohashi T, Abdel-Rahman HA, Flickinger GL, Mikhail G (August 1976). « Free and protein-bound plasma estradiol-17 beta during the menstrual cycle ». J. Clin. Endocrinol. Metab. 43(2): 436–45. doi:10.1210/jcem-43-2-436. PMID 950372.
- ^ Jump up to:a b Derived from mass values using molar mass of 314.46 g/mol
- ^ Jump up to:a b Bhattacharya Sudhindra Mohan (July/August 2005) Mid-luteal phase plasma progesterone levels in spontaneous and clomiphene citrate induced conception cycles J Obstet Gynecol India Vol. 55, No. 4 : July/August 2005 Pg 350-352
- ^ Jump up to:a b Dehydroepiandrosterone Sulfate (DHEA-S), Serum at Mayo Foundation For Medical Education And Research. Retrieved July 2012
- ^ Jump up to:a b c d Unit Code 91215 at Mayo Clinic Medical Laboratories. Retrieved April 2011
- ^ Jump up to:a b Antimullerian Hormone (AMH), Serum from Mayo Medical Laboratories. Retrieved April 2012.
- ^ Jump up to:a b Derived from mass values using 140,000 g/mol, as given in:
- Hampl R, Šnajderová M, Mardešić T (2011). « Antimüllerian hormone (AMH) not only a marker for prediction of ovarian reserve » (PDF). Physiological Research. 60 (2): 217–23. PMID 21114374.
- ^ Jump up to:a b Derived from mass values using molar mass of 4540g/mol. This molar mass was taken from: PROOPIOMELANOCORTIN; NCBI –> POMC Retrieved on September 28, 2009
- Jump up^ « Adrenocorticotropic Hormone:Normal ». WebMD. 09-03-2006. Retrieved 2008-11-09.Check date values in:
|date=
(help) - Jump up^ Derived from molar values using molar mass of 4540g/mol. This molar mass was taken from: PROOPIOMELANOCORTIN; NCBI –> POMC Retrieved on September 28, 2009
- ^ Jump up to:a b c d Biochemistry Reference Ranges at Good Hope Hospital Retrieved on Nov 8, 2009
- ^ Jump up to:a b c d Derived from molar values using molar mass of 362 g/mol
- ^ Jump up to:a b c d e f g h Friedrich N, Alte D, Völzke H, et al. (June 2008). « Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP) ». Growth Hormone & IGF Research. 18 (3): 228–37. doi:10.1016/j.ghir.2007.09.005. PMID 17997337.
- ^ Jump up to:a b c d e f g h i j k l m n o p Taken from the assay method giving the lowest and highest estimate, respectively, from Table 2 in: Beltran L, Fahie-Wilson MN, McKenna TJ, Kavanagh L, Smith TP (October 2008). « Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: evaluation and validation on common immunoassay platforms ». Clinical Chemistry. 54 (10): 1673–81. doi:10.1373/clinchem.2008.105312. PMID 18719199.
- ^ Jump up to:a b Derived from molar values using molar mass of 9.4 kDa
- ^ Jump up to:a b Table 2 in: Aloia JF, Feuerman M, Yeh JK (2006). « Reference range for serum parathyroid hormone ». Endocr Pract. 12 (2): 137–44. doi:10.4158/ep.12.2.137. PMC 1482827 . PMID 16690460.
- ^ Jump up to:a b Derived from mass values using molar mass of 9.4 kDa
- ^ Jump up to:a b c d e f Derived from molar values using molar mass 400.6 g/mol
- ^ Jump up to:a b c d Bender, David A. (2003). « Vitamin D ». Nutritional biochemistry of the vitamins. Cambridge: Cambridge University Press. ISBN 0-521-80388-8. Retrieved December 10, 2008 through Google Book Search.
- ^ Jump up to:a b c d Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. (September 2004). « Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y ». The American Journal of Clinical Nutrition. 80 (3): 752–58. PMID 15321818.
- ^ Jump up to:a b c d Reusch J, Ackermann H, Badenhoop K (May 2009). « Cyclic changes of vitamin D and PTH are primarily regulated by solar radiation: 5-year analysis of a German (50 degrees N) population ». Horm. Metab. Res. 41 (5): 402–07. doi:10.1055/s-0028-1128131. PMID 19241329.
- ^ Jump up to:a b c d e f g h Vasquez A, Cannell J (July 2005). « Calcium and vitamin D in preventing fractures: data are not sufficient to show inefficacy ». BMJ. 331 (7508): 108–09; author reply 109. doi:10.1136/bmj.331.7508.108-b. PMC 558659 . PMID 16002891.
- ^ Jump up to:a b Converted from values in mcU/mL by dividing with a factor of 11.2 mcU/mL per ng/(mL*hour), as given in:
- New Assays for Aldosterone, Renin and Parathyroid Hormone University of
Washington, Department of Laboratory Medicine. Retrieved Mars 2011
- ^ Jump up to:a b Pratt RE, Flynn JA, Hobart PM, Paul M, Dzau VJ (March 1988). « Different secretory pathways of renin from mouse cells transfected with the human renin gene ». The Journal of Biological Chemistry. 263 (7): 3137–41. PMID 2893797.
- ^ Jump up to:a b c d New Assays for Aldosterone, Renin and Parathyroid Hormone University of Washington, Department of Laboratory Medicine. Retrieved Mars 2011
- ^ Jump up to:a b Converted from values in ng/(mL*hour) by multiplying with a factor of 11.2 mcU/mL per ng/(mL*hour), as given in:
- New Assays for Aldosterone, Renin and Parathyroid Hormone University of
Washington, Department of Laboratory Medicine. Retrieved Mars 2011
- ^ Jump up to:a b Converted from mass values using molar mass of 360.44 g/mol
- ^ Jump up to:a b c d Tiu SC, Choi CH, Shek CC, et al. (January 2005). « The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling ». The Journal of Clinical Endocrinology and Metabolism. 90 (1): 72–78. doi:10.1210/jc.2004-1149. PMID 15483077.
- ^ Jump up to:a b c d e f Central Manchester University Hospitals –> Reference ranges Retrieved on July 9, 2009
- Jump up^ University of Kentucky Chandler Medical Center > Clinical Lab Reference Range Guide Retrieved on April 28, 2009
- ^ Jump up to:a b c d e Derived from mass values using molar mass of 441 mol−1
- ^ Jump up to:a b GPnotebook > B12 Retrieved on April 28, 2009
- ^ Jump up to:a b Derived form molar values using molar mass of 1355g/mol
- ^ Jump up to:a b Derived from mass values using molar mass of 1355g/mol
- ^ Jump up to:a b c d The Doctor’s Doctor: Homocysteine
- ^ Jump up to:a b c d Derived from molar values using molar massof 135 g/mol
- ^ Jump up to:a b Derived from mass values using molar mass of 176 grams per mol
- ^ Jump up to:a b c For Driving under the influence by country, see Drunk driving law by country
- Jump up^ Derived from mass values using molar mass of 46g/mol
- ^ Jump up to:a b c d e Derived from mass values using 64,500 g/mol. This molar mass was taken from: Van Beekvelt MC, Colier WN, Wevers RA, Van Engelen BG (2001). « Performance of near-infrared spectroscopy in measuring local O2 consumption and blood flow in skeletal muscle ». J Appl Physiol. 90 (2): 511–19. doi:10.1152/jappl.2001.90.2.511. PMID 11160049.
- ^ Jump up to:a b c d Normal Lab Values Archived 2014-12-16 at the Wayback Machine. at Marshall University Joan C. Edwards School of Medicine. Retrieved July 2013
- ^ Jump up to:a b c d e f g h molar concentration as given for hemoglobin above, but multiplied by 4, according to: Lodemann P, Schorer G, Frey BM (February 2010). « Wrong molar hemoglobin reference values-a longstanding error that should be corrected ». Annals of Hematology. 89(2): 209. doi:10.1007/s00277-009-0791-x. PMID 19609525.
- ^ Jump up to:a b c d Derived from mass concentration, using molar mass of 64,458 g/mol. This molar mass was taken from: Van Beekvelt MC, Colier WN, Wevers RA, Van Engelen BG (2001). « Performance of near-infrared spectroscopy in measuring local O2 consumption and blood flow in skeletal muscle ». J Appl Physiol. 90 (2): 511–519. doi:10.1152/jappl.2001.90.2.511. PMID 11160049.. Subsequently, 1 g/dL = 0.1551 mmol/L
- ^ Jump up to:a b c d e f g h lymphomation.org > Tests & Imaging > Labs > Complete Blood CountRetrieved on May 14, 2009
- ^ Jump up to:a b c d e f g h i j k l m n o p q r s t u Clinical Laboratory Medicine. By Kenneth D. McClatchey. Page 807.
- Jump up^ Determination of monocyte count by hematological analyzers, manual method and flow cytometry in polish population Central European Journal of Immunology 1-2/2006. (Centr Eur J Immunol 2006; 31 (1-2): 1-5) authors: Elżbieta Górska, Urszula Demkow, Roman Pińkowski, Barbara Jakubczak, Dorota Matuszewicz, Jolanta Gawęda, Wioletta Rzeszotarska, Maria Wąsik,
- ^ Jump up to:a b c d e gpnotebook.co.uk > blood constituents (reference range) Retrieved on May 14, 2009
- ^ Jump up to:a b Demirin H, Ozhan H, Ucgun T, Celer A, Bulur S, Cil H, Gunes C, Yildirim HA (2011). « Normal range of mean platelet volume in healthy subjects: Insight from a large epidemiologic study ». Thromb. Res. 128 (4): 358–60. doi:10.1016/j.thromres.2011.05.007. PMID 21620440.
- ^ Jump up to:a b Normal Values: RBC, Hgb, Hct, Indices, RDW, Platelets, and MPV (Conventional Units) From labcareplus. Retrieved 4 nov, 2010
- ^ Jump up to:a b Lozano M, Narváez J, Faúndez A, Mazzara R, Cid J, Jou JM, Marín JL, Ordinas A (1998). « [Platelet count and mean platelet volume in the Spanish population] ». Med Clin (Barc) (in Spanish). 110 (20): 774–77. PMID 9666418.
- ^ Jump up to:a b MedlinePlus Encyclopedia 003652
- ^ Jump up to:a b Antithrombin III at eMedicine
- ^ Jump up to:a b Antithrombin CO000300 in Coagulation Test Handbook at Massachusetts General Hospital. In turn citing:
- Elizabeth M. Van Cott, M.D., and Michael Laposata, M.D., Ph.D., « Coagulation. » In: Jacobs DS et al, ed. The Laboratory Test Handbook, 5th Edition. Lexi-Comp, Cleveland, 2001; 327-358.
- ^ Jump up to:a b [1] Retrieved on November 20, 2009
- ^ Jump up to:a b Miller A, Green M, Robinson D (January 1983). « Simple rule for calculating normal erythrocyte sedimentation rate ». British Medical Journal. 286 (6361): 266. doi:10.1136/bmj.286.6361.266. PMC 1546487 . PMID 6402065.
- Jump up^ Böttiger LE, Svedberg CA (1967). « Normal erythrocyte sedimentation rate and age ». Br Med J. 2 (5544): 85–87. doi:10.1136/bmj.2.5544.85. PMC 1841240 . PMID 6020854.
- Jump up^ « C-reactive protein ». GPnotebook.
- Jump up^ 2730 Serum C-Reactive Protein values in Diabetics with Periodontal Disease A.R. Choudhury, and S. Rahman, Birdem, Diabetic Association of Bangladesh, Dhaka, Bangladesh. (the diabetics were not used to determine the reference ranges)
- ^ Jump up to:a b c d Derived from mass using molar mass of 25,106 g/mol
- ^ Jump up to:a b Sipahi T, Kara C, Tavil B, Inci A, Oksal A (March 2003). « Alpha-1 antitrypsin deficiency: an overlooked cause of late hemorrhagic disease of the newborn ». Journal of Pediatric Hematology/Oncology. 25 (3): 274–75. doi:10.1097/00043426-200303000-00019. PMID 12621252.
- ^ Jump up to:a b Derived from mass values using molar mass of 44324.5 g/mol
- ^ Jump up to:a b Derived from molar values using molar mass of 44324.5 g/mol
- Jump up^ « Procalcitonin, Serum ». Mayo Clinic. Retrieved 2015-03-01.
- ^ Jump up to:a b c d e f g h i j The Society for American Clinical Laboratory Science > Chemistry Tests > Immunoglobulins Retrieved on Nov 26, 2009
- Jump up^ All values cited from Chronolab are given for ELISA
- ^ Jump up to:a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aqchronolab.com > Autoantibodies associated with rheumatic diseases > Reference rangesRetrieved on April 29, 2010
- ^ Jump up to:a b Rajkumar SV, Kyle RA, Therneau TM, et al. (August 2005). « Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance ». Blood. 106 (3): 812–17. doi:10.1182/blood-2005-03-1038. PMC 1895159 . PMID 15855274.
- Jump up^ « Reference range (amylase) ». GPnotebook.
- Jump up^ Ageno W, Finazzi S, Steidl L, et al. (2002). « Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes ». Archives of Internal Medicine. 162 (22): 2589–93. doi:10.1001/archinte.162.22.2589. PMID 12456231.
- Jump up^ Kline JA, Williams GW, Hernandez-Nino J (May 2005). « D-dimer concentrations in normal pregnancy: new diagnostic thresholds are needed ». Clinical Chemistry. 51 (5): 825–29. doi:10.1373/clinchem.2004.044883. PMID 15764641.
- ^ Jump up to:a b Gardner MD, Scott R (April 1980). « Age- and sex-related reference ranges for eight plasma constituents derived from randomly selected adults in a Scottish new town ». Journal of Clinical Pathology. 33 (4): 380–85. doi:10.1136/jcp.33.4.380. PMC 1146084 . PMID 7400337.
- ^ Jump up to:a b c d Finney H, Newman DJ, Price CP (January 2000). « Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance ». Annals of Clinical Biochemistry. 37 (1): 49–59. doi:10.1258/0004563001901524. PMID 10672373.
- ^ Jump up to:a b c d e f g h Derived from molar values by multiplying with the molar mass of 113.118 g/mol, and divided by 10.000 to adapt from μg/L to mg/dL
- ^ Jump up to:a b MedlinePlus Encyclopedia Glucose tolerance test
- ^ Jump up to:a b c Derived from molar values using molar mass of 180g/mol
- ^ Jump up to:a b Derived from mass values using molar mass of 180g/mol
- ^ Jump up to:a b « Diabetes – Prevention ». Cleveland Clinic. Retrieved 2016-06-23. Last revised 1/15/2013
- ^ Jump up to:a b c d Derived from mass values using molar mass of 90.08 g/mol
- ^ Jump up to:a b Derived from mass values using molar mass of 88.06 g/mol
- ^ Jump up to:a b Ketones at eMedicine
- ^ Jump up to:a b c d Page 700 in:
Richard C. Dart. Medical Toxicology. Lippincott Williams & Wilkins=year=2004. ISBN 9780781728454. - Jump up^ The UK Electronic Medical Compendium recommends 0.4–0.8 mmol/l plasma lithium level in adults for prophylaxis of recurrent affective bipolar manic-depressive illness Camcolit 250 mg Lithium Carbonate Revision 2 December 2010, Retrieved 5 May 2011
- ^ Jump up to:a b Amdisen A. (1978). « Clinical and serum level monitoring in lithium therapy and lithium intoxication ». J. Anal. Toxicol. 2 (5): 193–202. doi:10.1093/jat/2.5.193.
- ^ Jump up to:a b R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 851–54.
- Jump up^ One study (Solomon, D.; Ristow, W.; Keller, M.; Kane, J.; Gelenberg, A.; Rosenbaum, J.; Warshaw, M. (1996). « Serum lithium levels and psychosocial function in patients with bipolar I disorder ». The American Journal of Psychiatry. 153 (10): 1301–07. PMID 8831438.) concluded a « low » dose of 0.4–0.6 mmol/L serum lithium treatment for patients with bipolar 1 disorder had less side effects, but a higher rate of relapse, than a « standard » dose of 0.8–1.0 mmol/l. However, a reanalysis of the same experimental data (Perlis, R.; Sachs, G.; Lafer, B.; Otto, M.; Faraone, S.; Kane, J.; Rosenbaum, J. (2002). « Effect of abrupt change from standard to low serum levels of lithium: A reanalysis of double-blind lithium maintenance data ». The American Journal of Psychiatry. 159 (7): 1155–59. doi:10.1176/appi.ajp.159.7.1155. PMID 12091193.) concluded the higher rate of relapse for the « low » dose was due to abrupt changes in the lithium serum levels[improper synthesis?]
- ^ Jump up to:a b John Marx; Ron Walls; Robert Hockberger (2013). Rosen’s Emergency Medicine – Concepts and Clinical Practice. Elsevier Health Sciences. ISBN 9781455749874.